Consideration of regional difference in design and analysis of multi-regional trials

Published in 2010 by John Wiley & Sons, Ltd.

Bibliographic Details
Published in:Pharmaceutical statistics, Vol. 9, No. 3 (2010), p. 173-8
Main Author: Hung, H M James
Other Involved Persons: Wang, Sue-Jane ; O'Neill, Robert T
Format: electronic Article
Language:English
ISSN:1539-1612
Item Description:Date Completed 20.01.2011
Date Revised 16.03.2012
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
DOI:10.1002/pst.440
Subjects:
QR Code: Show QR Code
LEADER 02816nma a2200493 c 4500
001 NLM201872625
003 DE-601
005 20181228004712.0
007 cr uuu---uuuuu
008 180205s2010 000 0 eng d
024 7 |a 10.1002/pst.440  |2 doi 
028 5 2 |a pubmed19n0673.xml 
035 |a (DE-599)NLM20872619 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Hung, H M James 
245 1 0 |a Consideration of regional difference in design and analysis of multi-regional trials  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 20.01.2011 
500 |a Date Revised 16.03.2012 
500 |a published: Print 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Published in 2010 by John Wiley & Sons, Ltd. 
520 |a Clinical trial strategy, particularly in developing pharmaceutical products, has recently expanded to a global level in the sense that multiple geographical regions participate in the trial simultaneously under the same study protocol. The possible benefits of this strategy are obvious, at least from the cost and efficiency considerations. The challenges with this strategy are many, ranging from trial or data quality assurance to statistical methods for design and analysis of such trials. In many regulatory submissions, the presence of regional differences in the estimated treatment effect, whether they are different only in magnitude or in direction, often presents great difficulty in interpretation of the global trial results, particularly for the acceptability by the local regulatory authorities. This article presents a number of useful statistical analysis tools for exploration of regional differences and a method that may be worth consideration in designing a multi-regional clinical trial 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Drug Approval  |6 D017277  |a statistics & numerical data  |6 Q000706 
653 2 |a Factor Analysis, Statistical  |6 D005163 
653 2 |a Geography  |6 D005843 
653 2 |a Guidelines as Topic  |6 D017408 
653 2 |a Humans  |6 D006801 
653 2 |a *Internationality  |6 D038622 
653 2 |a *Multicenter Studies as Topic  |6 D015337  |a economics  |6 Q000191  |a standards  |6 Q000592  |a statistics & numerical data  |6 Q000706 
653 2 |a *Randomized Controlled Trials as Topic  |6 D016032 
653 2 |a Small-Area Analysis  |6 D017062 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
700 1 |a Wang, Sue-Jane 
700 1 |a O'Neill, Robert T 
773 0 8 |i in  |t Pharmaceutical statistics  |g Vol. 9, No. 3 (2010), p. 173-8  |q 9:3<173-8  |w (DE-601)NLM16636522X  |x 1539-1612 
856 4 1 |u http://dx.doi.org/10.1002/pst.440  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 9  |j 2010  |e 3  |h 173-8